Stock Price, Quote, News and Profile of SUMMIT THERAPEUTICS INC(NASDAQ:SMMT) stock

SUMMIT THERAPEUTICS INC

NASDAQ:SMMT (1/14/2025, 6:06:31 PM)

After market: 16.96 +0.31 (+1.86%)

16.65

-1.53 (-8.39%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%-166.67%

Sales Q2Q%-100%

CRS98.5

6 Month89.53%

Overview

Earnings (Last)10-30 2024-10-30/bmo

Earnings (Next)02-18 2025-02-18/bmo

Ins Owners84.57%

Inst Owners10.1%

Market Cap12.28B

Shares737.45M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts83.33

Short Float %17.29%

Short Ratio9.51

IPO10-14 2004-10-14

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The company is headquartered in Miami, Florida and currently employs 105 full-time employees. The company went IPO on 2004-10-14. The firm's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. The company develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.